Your browser doesn't support javascript.
loading
Incidence, associated factors and clinical impact of severe infections in a large, multicentric cohort of patients with systemic lupus erythematosus.
Rúa-Figueroa, Íñigo; López-Longo, Javier; Galindo-Izquierdo, María; Calvo-Alén, Jaime; Del Campo, Víctor; Olivé-Marqués, Alejandro; Pérez-Vicente, Sabina; Fernández-Nebro, Antonio; Andrés, Mariano; Erausquin, Celia; Tomero, Eva; Horcada, Loreto; Uriarte, Esther; Freire, Mercedes; Montilla, Carlos; Sánchez-Atrio, Ana; Santos, Gregorio; Boteanu, Alina; Díez-Álvarez, Elvira; Narváez, Javier; Martínez-Taboada, Víctor; Silva-Fernández, Lucía; Ruiz-Lucea, Esther; Andreu, José Luis; Hernández-Beriain, José Ángel; Gantes, Marian; Hernández-Cruz, Blanca; Pérez-Venegas, José; Pecondón-Español, Ángela; Marras, Carlos; Ibáñez-Barceló, Mónica; Bonilla, Gema; Torrente, Vicente; Castellví, Iván; Alegre, Juan José; Calvet, Joan; Marenco, Jose Luis; Raya, Enrique; Vázquez, Tomás; Quevedo, Victor; Muñoz-Fernández, Santiago; Rodríguez-Gómez, Manuel; Ibáñez, Jesús; Pego-Reigosa, José M.
Afiliación
  • Rúa-Figueroa Í; Rheumatology Department, Doctor Negrín University Hospital Las Palmas de Gran Canaria, Bco. de la Ballena s/n, 35020 Las Palmas, Spain. Electronic address: iruafer@gobiernodecanarias.org.
  • López-Longo J; Rheumatology Department, Gregorio Marañón University Hospital, Madrid, Spain.
  • Galindo-Izquierdo M; Rheumatology Department, Doce de Octubre University Hospital, Madrid, Spain.
  • Calvo-Alén J; Rheumatology Department, Sierrallana Hospital, Torrelavega, Spain.
  • Del Campo V; Preventive Medicine Service, Biomedical Research Institute of Vigo (IBIV), University Hospital Complex of Vigo, Vigo, Spain.
  • Olivé-Marqués A; Rheumatology Department, German Trials i Pujol Hospital, Badalona, Spain.
  • Pérez-Vicente S; Statistical Department, Research Unit, Spanish Society of Rheumatology (SER), Madrid, Spain.
  • Fernández-Nebro A; Rheumatology Department, Carlos Haya University Hospital, Málaga, Spain.
  • Andrés M; Rheumatology Department, Hospital of Alicante, Alicante, Spain.
  • Erausquin C; Rheumatology Department, Doctor Negrín University Hospital Las Palmas de Gran Canaria, Bco. de la Ballena s/n, 35020 Las Palmas, Spain.
  • Tomero E; Rheumatology Department, La Princesa University Hospital, Madrid, Spain.
  • Horcada L; Rheumatology Department, Hospital of Navarra, Pamplona, Spain.
  • Uriarte E; Rheumatology Department, Donostia Hospital, Donostia, Guipuzcoa, Spain.
  • Freire M; Rheumatology Department, University Hospital Complex of A Coruña, A Coruña, Spain.
  • Montilla C; Rheumatology Department, Salamanca University Hospital, Salamanca, Spain.
  • Sánchez-Atrio A; System Diseases and Oncology Service, Príncipe de Asturias University Hospital Alcalá de Henares, Madrid, Spain.
  • Santos G; Rheumatology Department, Marina Baixa Hospital, Alicante, Spain.
  • Boteanu A; Rheumatology Department, Ramon y Cajal University Hospital, Madrid, Spain.
  • Díez-Álvarez E; Rheumatology Department, Hospital of León, León, Spain.
  • Narváez J; Rheumatology Department, Bellvitge Hospital, Barcelona, Spain.
  • Martínez-Taboada V; Rheumatology Department, Marqués de Valdecilla University Hospital, Santander, Spain.
  • Silva-Fernández L; Rheumatology Department, University Hospital Complex of Ferrol, Ferrol, Spain.
  • Ruiz-Lucea E; Rheumatology Department, Basurto Hospital, Bilbao, Spain.
  • Andreu JL; Rheumatology Department, Puerta de Hierro-Majadahonda Hospital, Madrid, Spain.
  • Hernández-Beriain JÁ; Rheumatology Department, Hospital Insular of Gran Canaria, Las Palmas de Gran Canaria, Spain.
  • Gantes M; Rheumatology Department, University Hospital of Canarias, Tenerife, Spain.
  • Hernández-Cruz B; Rheumatology Department, Virgen Macarena Hospital, Sevilla, Spain.
  • Pérez-Venegas J; Rheumatology Department, Jerez de la Frontera University Hospital, Cádiz, Spain.
  • Pecondón-Español Á; Rheumatology Department, Miguel Servet University Hospital, Zaragoza, Spain.
  • Marras C; Rheumatology Department, Virgen de la Arrixaca University Hospital, Murcia, Spain.
  • Ibáñez-Barceló M; Rheumatology Department, Son Llatzer Hospital, Mallorca, Spain.
  • Bonilla G; Rheumatology Department, La Paz University Hospital, Madrid, Spain.
  • Torrente V; Rheumatology Department, Hospital of Hospitalet-Moisés Broggi CSI, Barcelona, Spain.
  • Castellví I; Rheumatology Unit, Santa Creu i Sant Pau Hospital, Barcelona, Spain.
  • Alegre JJ; Rheumatology Department, Dr. Peset Hospital, Valencia, Spain.
  • Calvet J; Rheumatology Department, Parc Taulí Hospital, Barcelona, Spain.
  • Marenco JL; Rheumatology Department, Virgen de Valme University Hospital, Sevilla, Spain.
  • Raya E; Rheumatology Department, San Cecilio Hospital, Granada, Spain.
  • Vázquez T; Rheumatology Department, Lucus Augusti Hospital, Lugo, Spain.
  • Quevedo V; Rheumatology Unit, Monforte Hospital, Lugo, Spain.
  • Muñoz-Fernández S; Rheumatology Department, Infanta Sofía University Hospital, Madrid, Spain.
  • Rodríguez-Gómez M; Rheumatology Department, Hospital Complex of Ourense, Orense, Spain.
  • Ibáñez J; Rheumatology Unit, POVISA Medical Center, Vigo, Spain.
  • Pego-Reigosa JM; Rheumatology Department, Biomedical Research Institute of Vigo (IBIV), University Hospital Complex of Vigo, Vigo, Spain.
Semin Arthritis Rheum ; 47(1): 38-45, 2017 08.
Article en En | MEDLINE | ID: mdl-28259425
ABSTRACT

OBJECTIVES:

To estimate the incidence of severe infection and investigate the associated factors and clinical impact in a large systemic lupus erythematosus (SLE) retrospective cohort.

METHODS:

All patients in the Spanish Rheumatology Society Lupus Registry (RELESSER) who meet ≥4 ACR-97 SLE criteria were retrospectively investigated for severe infections. Patients with and without infections were compared in terms of SLE severity, damage, comorbidities, and demographic characteristics. A multivariable Cox regression model was built to calculate hazard ratios (HRs) for the first infection.

RESULTS:

A total of 3658 SLE patients were included 90% female, median age 32.9 years (DQ 9.7), and mean follow-up (months) 120.2 (±87.6). A total of 705 (19.3%) patients suffered ≥1 severe infection. Total severe infections recorded in these patients numbered 1227. The incidence rate was 29.2 (95% CI 27.6-30.9) infections per 1000 patient years. Time from first infection to second infection was significantly shorter than time from diagnosis to first infection (p < 0.000). Although respiratory infections were the most common (35.5%), bloodstream infections were the most frequent cause of mortality by infection (42.0%). In the Cox regression analysis, the following were all associated with infection age at diagnosis (HR = 1.016, 95% CI 1.009-1.023), Latin-American (Amerindian-Mestizo) ethnicity (HR = 2.151, 95% CI 1.539-3.005), corticosteroids (≥10mg/day) (HR = 1.271, 95% CI 1.034-1.561), immunosuppressors (HR = 1.348, 95% CI 1.079-1.684), hospitalization by SLE (HR = 2.567, 95% CI 1.905-3.459), Katz severity index (HR = 1.160, 95% CI 1.105-1.217), SLICC/ACR damage index (HR = 1.069, 95% CI 1.031-1.108), and smoking (HR = 1.332, 95% CI 1.121-1.583). Duration of antimalarial use (months) proved protective (HR = 0.998, 95% CI 0.997-0.999).

CONCLUSIONS:

Severe infection constitutes a predictor of poor prognosis in SLE patients, is more common in Latin-Americans and is associated with age, previous infection, and smoking. Antimalarials exerted a protective effect.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Corticoesteroides / Antirreumáticos / Inmunosupresores / Infecciones / Lupus Eritematoso Sistémico / Antimaláricos Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Female / Humans / Male Idioma: En Revista: Semin Arthritis Rheum Año: 2017 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Corticoesteroides / Antirreumáticos / Inmunosupresores / Infecciones / Lupus Eritematoso Sistémico / Antimaláricos Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Female / Humans / Male Idioma: En Revista: Semin Arthritis Rheum Año: 2017 Tipo del documento: Article